The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
An exploratory study on prediction of risk for abemaciclib-induced interstitial lung disease or hepatotoxicity by specific human leukocyte antigen alleles.
 
Chiyo K. Imamura
Employment - Moderna Therapeutics (I); Novartis (I)
Honoraria - Kirin Pharmaceuticals; Otsuka; Taiho Pharmaceutical
Research Funding - Lilly Japan
 
Taisei Mushiroda
No Relationships to Disclose
 
Mari Hosonaga
No Relationships to Disclose
 
Junji Tsurutani
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Lilly Japan; Nihonkayaku; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo; Daiichi Sankyo; Lilly; Seagen
Research Funding - Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Kirin (Inst); Lilly (Inst); MSD Oncology (Inst); Nihonkayaku (Inst); Sant Joan de Déu Research Foundation (FSJD) (Inst); West Japan Oncology Group (Inst); West Japan Oncology Group (Inst)
 
Michiko Tsuneizumi
No Relationships to Disclose
 
Takehiro Yanagawa
Honoraria - Eisai; Lilly; Pfizer
 
Hiroko Bando
Honoraria - Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Kyowa Kirin; Lilly Japan; MSD K.K; Pfizer
 
Yumi Fujimoto
Speakers' Bureau - Daiichi Sankyo; Lilly Japan; MSD
 
Yasuyuki Kojima
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Exact Sciences; Kyowa Hakko Kirin; Lilly Japan; MSD; Pfizer; Taiho Pharmaceutical
 
Kentaro Tamaki
No Relationships to Disclose
 
Takayuki Iwamoto
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Exact Sciences; Kyowa Kirin; MSD K.K; Takeda
Consulting or Advisory Role - Chugai Pharma
Research Funding - Pfizer
 
Takafumi Sangai
Honoraria - AstraZeneca Japan; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Kaken Pharmaceutical; Kyowa Hakko Kirin; Lilly Japan; Maruho; Miyarisan pharmaceutical; MSD; Nihonkayaku; PDRadiopharma; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Eisai (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Ishikawa
Honoraria - AstraZeneca Japan; Daiichi Sankyo; Eisai; Lilly Japan; Nippon Kayaku; Pfizer; Taiho Pharmaceutical; Takeda
 
Yuichiro Kikawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Lilly Japan; Novartis; Pfizer; Taiho Pharmaceutical
 
Hirofumi Mukai
Honoraria - Daiichi Sankyo; Taiho Pharmaceutical; Takeda